Pricing Log in Create free account
Friday 6 November 2026 Export RVMD’s income statement to Excel — free account

Revolution Medicines, Inc.

RVMD Healthcare Biotechnology

Revolution Medicines, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $11.6 million, down 67.3% from fiscal 2022.

Revenue
+1,188.7%
EPS
−18.0%
Free cash flow
−99.1%
Total debt
+322.7%

Quarter to September 2026, against a year earlier

193.41 15.76 +8.87%
Market cap
$38.1B
P/E
0.0×
Fwd P/E
−11.9×
Dividend yield
—
F-score
4/9
Altman Z
7.73
Beneish M
−4.29
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Revolution Medicines, Inc. (RVMD) SEC filings, changes and red flags

Red flags

Filings

Form Period Filed What it reports Flags
10-Q Sep 30, 2026 P1I2: 19 added · 7 removed · 51 modified
P2I1A: no comparison — low extraction confidence 		Short cash runway Share dilution
8-K Nov 4, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Oct 8, 2026 2.03 Creation of a direct financial obligation; 8.01 Other events
8-K Aug 27, 2026 1.01 Entry into a material definitive agreement; 2.03 Creation of a direct financial obligation
8-K Aug 26, 2026 8.01 Other events
10-Q Jun 30, 2026 P1I2: 11 added · 7 removed · 38 modified
P2I1A: no comparison — low extraction confidence
8-K Aug 5, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Jun 18, 2026 5.02 Departure or appointment of directors or officers; 5.07 Submission of matters to a vote of security holders Officer departure
10-Q Mar 31, 2026
8-K May 6, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Apr 14, 2026 1.01 Entry into a material definitive agreement; 2.03 Creation of a direct financial obligation; 8.01 Other events; 9.01 Financial statements and exhibits
8-K Apr 14, 2026 8.01 Other events; 9.01 Financial statements and exhibits
8-K Apr 13, 2026 8.01 Other events
10-K Dec 31, 2025 1: 49 added · 114 removed · 51 modified
1A: 38 added · 27 removed · 110 modified
7: 31 added · 50 removed · 34 modified
8-K Feb 25, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Sep 30, 2025
8-K Nov 5, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Oct 16, 2025 8.01 Other events
8-K Sep 10, 2025 8.01 Other events
10-Q Jun 30, 2025
8-K Aug 6, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Mar 31, 2025
8-K May 7, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-K Dec 31, 2024
8-K Feb 26, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Sep 30, 2024
8-K Nov 6, 2024 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Jun 30, 2024
8-K Aug 5, 2024 2.02 Results of operations and financial condition; 5.02 Departure or appointment of directors or officers; 9.01 Financial statements and exhibits
8-K May 8, 2024 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Feb 26, 2024 2.02 Results of operations and financial condition
8-K Jan 9, 2024 2.02 Results of operations and financial condition; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
8-K Nov 6, 2023 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits

From the company’s filings on sec.gov. Red flags are raised by rules over the filings’ own data and text; they are not investment advice.